Status:

COMPLETED

Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

Lead Sponsor:

NeurogesX

Conditions:

Herpes Zoster

Neuralgia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local...

Eligibility Criteria

Inclusion

  • Key Eligibility Criteria:
  • Must have had for at least 3 months painful diabetic neuropathy, or postherpetic neuralgia, or painful HIV-associated neuropathy, with moderate to severe pain on average.
  • Must not have significant pain due to other causes (for example, arthritis).
  • Must have intact skin at the treatment area.
  • Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (12 weeks).
  • Must not use topical pain medications on painful areas.
  • Must be able to comply with study requirements such as completing daily pain diary and attending study visits and refrain from extensive travel during study participation.
  • Must be at least 18 years old, not pregnant, and able to take care of self independently, with only occasional assistance if needed.
  • No significant medical problems of the heart, kidneys, liver or lungs, or cancer.
  • No history or current problem with substance abuse.

Exclusion

    Key Trial Info

    Start Date :

    Trial Type :

    INTERVENTIONAL

    End Date :

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT00082316

    Last Update

    January 11 2008

    Active Locations (17)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (17 locations)

    1

    NeurogesX Investigational Site

    Huntsville, Alabama, United States, 35801

    2

    NeurogesX Investigational Site

    Mobile, Alabama, United States, 36608

    3

    NeurogesX Investigational Site

    Phoenix, Arizona, United States, 85023

    4

    NeurogesX Investigational Site

    Fountain Valley, California, United States, 92708